High-Shear Microfluidic Thrombosis Assay
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to characterize a new test to assess the rate and time it takes to form a blood clot in people who either do or do not take aspirin.
Full description
It is estimated that approximately 25% of people are resistant to aspirin, or do not respond to its effect. These individuals have a four fold higher risk of a heart attack or stroke compared to those who respond to aspirin. Current tests for determining those who are aspirin resistant are not reliable. This study is assessing the effectiveness of a new assay in determining the rate and time it takes for people who are or are not on aspirin in forming a blood clot.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for "no aspirin" group:
- have not taken aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or clopidogrel in the previous 10 days
- no history of myocardial infarction, ischemic stroke, or other ischemic event
Inclusion Criteria for "aspirin daily" group:
- have taken aspirin daily over the last 10 days or more
- no history of myocardial infarction, ischemic stroke, or other ischemic event
Inclusion Criteria for "new to aspirin" group:
- have not previously been prescribed aspirin, but have been prescribed aspirin at their present appointment, e.g. a high calcium plaque score on CT
- no history of myocardial infarction, ischemic stroke, or other ischemic event
Exclusion Criteria:
- a known bleeding or thrombotic disorder
Exclusion Criteria for "new to aspirin" group:
- a known bleeding or thrombotic disorder
- have taken aspirin, other NSAIDs, clopidogrel, or an anticoagulant in the previous 10 days
Trial design
16 participants in 3 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal